Recently, PLCγ1 inhibition has emerged as a therapeutic target for hematologic cancers and PLCγ1 phosphorylation status is a biomarker for metastatic risk in luminal breast cancer [11, 42, 43]. Here, PLCG1 is linked to breast carcinoma.